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ABSTRACT 
To determine antimycobacterium and dTDP rhamnose inhibitor activity of the synthesized azetidinone, thiazolidinone derivatives of thiazole, we 
studied different derivatives for the activity. One pot synthesis of 2-amino-4-methylthiazole-5-carboxylic acid ethyl ester has been carried out 
and synthesized different derivative compounds. Compounds were tested for antimicrobial activity against different strains of microorganism 
and antitubercular activity against M. tuberculosis H37Rv. Compounds 7c, 7d, 7i, 8d, 8e, 8g and 8h, were showed antimicrobial activity against 
Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Salmonella typhosa using Gentamycin as standard, while 7b, 7e, 7f, 7i, 8b, 8e, 8f 
and 8i showed very strong antimycobacterial activity using rifampicine as a standard. Thiazole derivatives especially with carbonyl group 
scaffold inhibit an enzyme RmlC, which is an essential component for the biosynthesis of dTDP-rhamnose and produce good antimycobacterium 
and antimicrobial activity. 
Keywords: Thiazole, thiazolidinone derivatives, azetidinone derivative, well diffusion method, broth microdilution assay, antitubercular activity, 
antimicrobial activity. 
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INTRODUCTION  
Microbial infections remain the major cause of death over 
the world. Emergence of multi-drug resistant to different 
infectious organisms like M. tuberculosis made the condition 
most alarming1, 2. Therefore, there is an urgent demand for a 
new class of antimicrobial agent with a different mode of 
action and it led medicinal chemists to explore a wide variety 
of chemical structures. A de novo structural design has 
demonstrated that the thiazole derivatives especially with 
carbonyl group scaffold inhibit an enzyme RmlC, which is an 
essential component for the biosynthesis of dTDP-
rhamnose3.  While reports4, 5 are available stating emergence 
of thiazole as potent antibacterial agent. β-Lactams are the 
most successful antimicrobials6,7,8,9. Till recent days, unless 
microorganisms targeted, are not resistant. (By production 
of β-lactamase) Appreciation of these finding towards the 
development of novel antimicrobial agents, coupled with our 
program of drug design10, 11. It was thought to club together 
two or three nuclei having different sites or mechanism of 
action. This initiated us constructing compounds containing 
both the thiazole, azetidinone & thiazolidinone ring systems 
in the same matrix to serve as a new scaffold. 
MATERIAL AND METHODS 
Scheme (Figure 1) for synthesis of 2-amino-4-
methylthiazole-5-carboxylic acid ethyl ester (3)12 and its 
derivatives (4-8)10, 11. The various chemicals used in the 
synthesis of the titled compounds were purchased from, 
sigma-aldrich pvt ltd, spectrochem pvt ltd and S.D. fine chem 
pvt ltd. The nucleus and its derivatives were analyzed by 
different ways. The melting points were recorded on 
electrothermal apparatus and are uncorrected. 1H NMR 
spectra on a Bruker Avance 300 MHz instrument using CDCl3 
as solvent using TMS as internal standard; the chemical 
shifts (δ) were reported in ppm with coupling constants (J) 
are given in Hz. Signal multiplicities were represented by s 
(singlet), d (doublet), t (triplet), ds (double singlet), dd 
(double doublet), m (multiplet) and bs (broad singlet). The 
purity of the compounds was checked on silica gel coated Al 
plates (Merck) 
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Figure 1: Scheme for synthesis of 2-amino-4-methylthiazole-5-carboxylic acid ethyl ester(3) and its derivatives(4-8) 
 
Synthesis of Ethyl-2-substitutedamido-4-methylthiazol-5-
carboxylate (4). 
Ethyl-2-amino–4-methylthiazol–5-carboxylate (3) (1 mmol, 
2 g) was taken in a 50 mL round bottom flask. Acetic 
anhydride or benzoyl chloride (1 mmol) was added to the 
above solution slowly with constant stirring. The mixture 
was then refluxed for 1 h. The solution was poured in ice-
cold water with vigorous stirring, to yield precipitate. The 
suspension was then heated to boiling and cooled under tap 
water. The product was filtered, dried and recrystallized by 
ethanol to get (4);  
Synthesis of 2-Substitutedamido-4-methylthiazol-5-
carboxylic acid hydrazide (5) 
Ethyl-2-substitutedamido-4-methylthiazol-5-carboxylate (4) 
(6 mmol) and 98% hydrazine hydrate (1.2 mmol) was taken 
in a round bottom flask and heated for five minutes. Ethanol 
was added to the above solution till the mixture becomes 
clear solution. Then the mixture was refluxed for 4 h on 
water bath maintaining the temperature between 70-75 ºC. 
The excess of alcohol was removed by distillation. On 
cooling, fine white precipitate of 2-substitutedamido-4-
methylthiazol-5-carboxylic acid hydrazide (5) was obtained. 
The product was washed with water, filtered and dried and 
recrystallized from water.  
Synthesis of N-[5-(arylidene-hydrazinocarbonyl)-4-
methyl-thiazol-2-yl]-substituted-amide (6).  
2-substitutedamido-4-methylthiazol-5-carboxylic acid 
hydrazide (5)  (1 mmol) and aryl aldehyde (1 mmol) was 
taken in ethanol (15 mL), 3-4 drops of concentrated H2SO4 
was added and refluxed for 2 h. The reaction mixture was 
cooled and the solid separated was filtered, washed with 
cold ethanol, and recrystallized from ethanol to obtained N-
[5-(arylidene-hydrazinocarbonyl)-4-methyl-thiazol-2-yl]-
substituted-amide (6). 
Synthesis of 2-Substituted-amino-4-methyl-thiazol-5-
carboxalic acid (3-chloro-2-oxo-4-aryl-azetidin-1-yl)-
amide (7).  
N-[5-(arylidene-hydrazinocarbonyl)-4-methyl-thiazol-2-yl]-
substituted-amide (6) (1 mmol) was dissolved in 25 mL 1, 4-
dioxane.  Triethylamine (1 mmol, 1 mL) was added drop 
wise with constant stirring to the solution, followed by 
similar addition of chloroacetyl chloride (1 mmol, 2 mL). The 
mixture was then stirred for 30 min followed by refluxing for 
5 h. It was then cooled and filtered to remove insoluble salts.  
Excess of solvent was then distilled off. The concentrated 
solution was poured on crushed ice with vigorous stirring. 
The precipitate formed was filtered, washed with water and 
recrystallized by ethanol and water. 
Synthesis of 2-Substituted-amino-4-methyl-thiazol-5-
carboxalic acid (4-oxo-2-aryl-thiazolidin-3-yl)-amide (8).  
N-[5-(arylidene-hydrazinocarbonyl)-4-methyl-thiazol-2-yl]-
substituted-amide (6) (1 mmol) was dissolved in 20 mL 
anhydrous 1, 4-dioxane. Thioglycollic acid (1.5 mmol, 1.38 g) 
was added slowly drop wise with stirring. A pinch of 
aluminium chloride was added and the mixture was then 
stirred for 30 min followed by refluxing for 6 h. It was then 
cooled and filtered to remove insoluble salt. The 
concentrated solution was poured into aqueous saturated 
solution of NaHCO3 with stirring. The precipitate formed was 
filtered, washed with water and recrystallized by alcohol and 
water. 
Antitubercular activity 
Primary screening was conducted at 6.25 µg mL-1 against M. 
tuberculosis H37Rv (ATCC 27294) in BACTEC 12B medium 
using a broth microdilution assay, the Microplate Alamar 
Blue Assay (MABA)13. Compounds exhibiting fluorescence 
were tested in the BACTEC 460 radiometric system14. 
Compounds showing more than/95% inhibition in the 
primary screening were considered active and then re-tested 
at a lower concentrations against M. tuberculosis H37Rv in 
order to determine the actual MIC, using MABA. The MIC is 
defined as the lowest concentration effecting a reduction in 
fluorescence of 95% with respect to the controls. Rifampin 
(RMP) was used as the reference compound (RMP MIC 
=/0.015-0.125 mg mL-1). We also have done cytotoxicity 
analysis of the above-synthesized compounds, using neutral 
red uptake by using Vero-C-1008 cell line at various 
concentrations (6.25 µg/mL to 50 µg/mL), none of them 
were found toxic. Hence the activities of the above-
synthesized compounds were not due to cytotoxicity. 
Antimicrobial activity 
Microbial strains- Staphylococcus aureus ATCC 23564, 
Escherichia coli ATCC35218, Pseudomonas aeruginosa ATCC 
25619, Salmonella typhi ATCC 10749 
The compounds listed in the table 3 were screened for the 
antimicrobial activity against different microorganisms using 
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well diffusion method15,16, where 50µM and 100 µM 
concentrations were taken for activity in nutrient agar 
medium. Chloroform was used as solvents and antibiotic 
Gentamycin was used as standard. The culture was kept for 
24 hours. The nutrient agar medium, 20 mL was poured into 
the sterile petri dishes. To the solidified plates, wells were 
made using a sterile cork borer 10 mm in diameter. The 24 
hour (at 24-28 °C) subcultured bacteria was inoculated in 
the petri-plates, with a sterile cotton swab dipped in the 
nutrient broth medium. After inoculating, the compounds 
were dissolved separately with the chloroform solvent and 
poured into the wells with varying concentrations ranging 
from 50 & 100 µM using a micropipette. The plates were left 
over for 24 hours at 24-28 °C. The antibiotic Gentamycin was 
used as a standard for comparative study. The percentage of 
inhibition was calculated by the formula; percent Inhibition 
= Diameter of the inhibition zone x 100 
RESULTS 
 
Table 1: MIC and growth inhibition of the compounds against M. tuberculosis H37Rv 
Comp R Ar MIC (µg/mL-1)a GI (%)b 
7a NHCOCH3  -C6H5 <6.25 ---- 
7b NHCOCH3 -4-F -C6H4 <6.25 100 
7c NHCOCH3 -3,4,5-CH3O -C6H2 <6.25 ---- 
7d NHCOCH3 -4-(CH3)2N-C6H4 <6.25 ---- 
7e NHCOCH3 -2-F -C6H4 <6.25 100 
7f NHCOC6H5 -4-Cl -C6H4 <6.25 96 
7g NHCOC6H5 -3-NO2 -C6H4 <6.25 ---- 
7h NHCOC6H5 -4-OH -C6H4 <6.25 ---- 
7i NHCOC6H5 -2-Cl -C6H4 <6.25 98 
7j NHCOC6H5 -2-NO2 -C6H4 <6.25 ---- 
8a NHCOCH3 -C6H5 <6.25 ---- 
8b NHCOCH3 -4-F -C6H4 <6.25 98 
8c NHCOCH3 -3,4,5-CH3O -C6H2 <6.25 ---- 
8d NHCOCH3 -4-(CH3)2N-C6H4 <6.25 ---- 
8e NHCOCH3 -2-F -C6H4 <6.25 100 
8f NHCOC6H5 -4-Cl -C6H4 <6.25 97 
8g NHCOC6H5 -3-NO2 -C6H4 <6.25 ---- 
8h NHCOC6H5 -4-OH -C6H4 <6.25 ---- 
8i NHCOC6H5 -2-Cl -C6H4 <6.25 97 
8j NHCOC6H5 -2-NO2 -C6H4 <6.25 ---- 
aMIC of rifampin: 0.015-0.125 mg mL-1 versus M. tuberculosis H37Rv (97% inhibition). 
                              bGrowth inhibition of virulent H37Rv strain of M. tuberculosis.  
 Table 2: Second level Actual minimum inhibitory concentration of the compounds. 
 
 
 
 
a Actual minimum inhibitory concentration (MABA assay). 
Table 3: Antibacterial activity of the synthesized compounds. 
Comp. 
Organisms 
Comp. 
Organisms 
Sa Pa Ec St Sa Pa Ec St 
7a 18 17 14 12 8a 18 16 10 12 
7b 18 16 15 14 8b 20 16 10 10 
7c 22 20 18 14 8c 22 22 20 16 
7d 25 22 20 16 8d 26 24 22 18 
7e 20 20 18 14 8e 36 34 30 30 
7f 16 16 20 16 8f 24 22 20 18 
7g 16 10 10 18 8g 22 11 24 24 
7h 11 17 15 22 8h 22 22 20 20 
7i 32 32 30 36 8i 36 38 32 32 
7j 16 16 12 12 8j 16 16 12 14 
Gent 34 35 31 30 Gent 34 35 31 30 
Sa: Staphylococcus aureus, Ec: Escherichia coli, Pa: Pseudomonas aeruginosa, St: Salmonella typhosa, Gent: Gentamycin 
Antitubercular activity 
During the preliminary screening 20 compounds 7a-7j and 
8a-8j were tested (Table 1) at 6.25 µg/mL concentration for 
their antimycobacterial activity, eight compounds 7b, 7e, 7f, 
7i, 8b, 8e, 8f and 8i have exhibited more than 96% inhibition 
at this concentration while other compounds exhibited less 
than 90% inhibition at the same concentration. SAR of the 
synthesized compounds suggests that most of these 
compounds are very much similar to each other, differing in 
the substitutions on the aryl ring. And it can be seen that 
compounds having halogen are more potent than other. On 
SN MIC (µM)a SN MIC (µM)a 
7b 6.25 8b 3.13 
7e 1.56 8e 6.25 
7f 3.13 8f 6.25 
7i 0.39 8i 0.78 
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the other hand, in secondary screening (Table-2), only 7i, 7e 
and 8i were found to have promising antimycobacterial 
activity. Other compounds are not as active as the earlier 
ones. Although we have not been able to substantially 
enhance the activity of these compounds in the present study, 
the data presented here are encouraging and deserve further 
investigation. 
Antimicrobial activity 
It has been found that all the compounds tested showed 
broad spectrum of inhibitory properties. From the 
antibacterial screening it was observed that all the 
compounds exhibited activity against all the organisms 
employed. Looking at the structure activity relationship, 
marked inhibition in bacteria was observed in the 
compounds 7i, 8i and 8e whereas 7c, 7d, 8d, 8f, 8g and 8h 
have shown moderate activity and others showed least 
activity (Table 3). 
DISCUSSION 
2-Amino-4-methyl-thiazole-5-carboxylic acid ethyl ester (3) 
was synthesized by cyclization of 2-bromo-ethylacetoacetate 
with thiourea. The internal bromination of ethylacetoacetate 
was achieved by treatment with N-bromosuccinamide. Free 
radical reaction generated by benzoyl peroxide was used 
initiator. The reactive amino group was then protected, either 
by acetylation or benzoylation process to yield 2-substituted-
amino-4-methyl-thiazole-5-carboxylic acid ethyl ester 
(4a,4b). Chemical transformation of compound (4a,4b) to 
hydrazide derivative (5a,5b) was achieved. The free amino 
group of hydrazide was condensed to schiff’s base (6a-6j), by 
reacting with arylaldehydes in ethanol, which on treatment 
with mercaptoacetic acid and chloroacetyl chloride gave 
thiazolidinone (8a-8j) and azetidinone (7a-7j) derivatives 
respectively. Compounds 7c, 7d, 7i, 8d, 8e, 8g and 8h have 
shown antimicrobial activity against microorganism, while 
7b, 7e, 7f, 7i, 8b, 8e, 8f and 8i have shown very strong 
antimycobacterial activity. Recent studies have pointed to the 
essential nature of rhamnose in some cell walls and capsules. 
L-Rhamnose is a 6-deoxyhexose that is found in a variety of 
different glycol-conjugates in the cell walls of pathogenic 
bacteria. The precursor of L-rhamnose is dTDP-L-rhamnose, 
which is synthesised from glucose- 1-phosphate and 
deoxythymidine triphosphate (dTTP) via a pathway requiring 
enzymes. Significantly this pathway does not exist in humans 
and all four enzymes therefore represent potential 
therapeutic targets. dTDP-D-glucose 4,6-dehydratase (RmlB; 
EC 4.2.1.46) is the second enzyme in the dTDP-L-rhamnose 
biosynthetic pathway. The immediate source of rhamnose in 
carbohydrate polymers is dTDP-L-rhamnose. The other 
enantiomer, D-rhamnose, is primarily utilised by 
Pseudomonas aeruginosa. A de novo structural design has 
demonstrated that the thiazole derivatives especially with 
carbonyl group scaffold inhibit an enzyme RmlC, which is an 
essential component for the biosynthesis of dTDP-rhamnose. 
While, reports are available stating emergence of thiazole as 
potent antibacterial agent. The structure has been refined to 
a crystallographic R-factor of 20.4% and an R-free value of 
24.9% with good stereochemistry. (By production of β-
lactamase) Appreciation of these finding towards the 
development of novel antimicrobial agents, coupled with our 
program of drug design, it was thought to club together two 
or three nuclei having different sites or mechanism of action. 
Hence the synthesized and identified compounds possess 
antimycobacterium potential as well as are dTDP-rhamnose 
inhibitors. 
 
CONCLUSION 
Thiazole derivatives especially with carbonyl group scaffold 
inhibit an enzyme RmlC, which is an essential component for 
the biosynthesis of dTDP-rhamnose and produce good 
antimycobacterium and antimicrobial activity. 
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